- Home
- RUM vs PTGX Comparison
RUM vs PTGX Comparison
Compare RUM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 135 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 5.2B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RUM | PTGX |
|---|---|---|
| Price | $4.68 | $99.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $10.00 | ★ $106.67 |
| AVG Volume (30 Days) | ★ 1.9M | 828.9K |
| Earning Date | 03-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $209.98 | $867.86 |
| Revenue Next Year | $40.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.65 | $39.60 |
| 52 Week High | $10.99 | $105.69 |
Technical Indicators
Market Signals| Indicator | RUM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.04 | 57.60 |
| Support Level | N/A | $76.63 |
| Resistance Level | $6.94 | $100.00 |
| Average True Range (ATR) | 0.21 | 4.85 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 1.55 | 57.05 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.